Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C82.-C82.7C82.9C83.3C84.4C84.6C84.7C85.2C86.1C86.2C86.5C94.7-MeSHLeukemia, Large Granular LymphocyticLymphoma, Large-Cell, AnaplasticSequenceMTRX10/THAL50/PRED0.5, T-LGL (PID3005) -|- THAL50, maint. (PID3008)STUDY - levelChemotherapyChemo-substanceGemcitabineMethotrexateNivolumabOxaliplatinPrednisoloneThalidomideChemo-substanceGemcitabineMethotrexateNivolumabOxaliplatinPrednisoloneThalidomideChemo-substanceGemcitabineMethotrexateNivolumabOxaliplatinPrednisoloneThalidomideChemo-substanceGemcitabineMethotrexateNivolumabOxaliplatinPrednisoloneThalidomideNo. Substances123 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCalcium carbonateCiprofloxacinColecalciferolCotrimoxazoleDexamethasoneFolic acidGranisetronPantoprazolePegfilgrastimSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCalcium carbonateCiprofloxacinColecalciferolCotrimoxazoleDexamethasoneFolic acidGranisetronPantoprazolePegfilgrastimSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCalcium carbonateCiprofloxacinColecalciferolCotrimoxazoleDexamethasoneFolic acidGranisetronPantoprazolePegfilgrastimSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCalcium carbonateCiprofloxacinColecalciferolCotrimoxazoleDexamethasoneFolic acidGranisetronPantoprazolePegfilgrastimNo. Substances1367Protocol classificationTherapy classificationalternativeStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseConsolidationMaintenanceTherapy intentiondisease controlpalliativeRisksEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HyperglycemiaIncrease AminotransferasesNeuropathyNeutropeniaThromboembolic Event only studiesPublicationAuthorHeld GYu YDiseaserezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2T-Zell Leukämie der großen granulierten Lymphozyten mit Therapieindikation, ErstlinieOriginChinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Protocols in Revision 6 protocols foundMethotrexate 10 / Thalidomide 50 / Prednisolone 0.5 - Thalidomide 50, T-cell leukemia of large granular lymphocytes, maintenance (PID3008 V1.0)Methotrexate 10 / Thalidomide 50 / Prednisolone 0.5, T-cell leukemia of large granular lymphocytes (PID3005 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
